PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II trial [abstract] - Park, K; Heo, D S; Cho, B (J Clin Oncol, 2010)
et al.